Ipamorelin Dosage Calculator — mcg to mL and Syringe Units

One study, intravenous, single dose — and what that leaves unanswered

The entire published human record for ipamorelin is Gobburu et al. 1999: 40 healthy men, 8 per dose level, a single 15-minute intravenous infusion. Pharmacokinetics were dose-proportional across a 33-fold range, growth hormone peaked at 0.67 hours, and it returned to negligible within about 6 hours at every dose tested.

Three things that study cannot tell you, and no other study does either. It used the intravenous route, so it says nothing about subcutaneous bioavailability — the route every vial sold online is intended for. It was a single dose, so there is no repeat-dose data, no accumulation data and no tolerance data. And it measured growth hormone release, not any clinical outcome, so nothing in it speaks to whether anything downstream changes.

A terminal half-life of about 2 hours with growth hormone gone within 6 is also the reason the dosing patterns circulating online cannot be derived from it: the study established how fast the signal disappears, not how often it should be repeated.

Rejected for 503A, still flagged under 503B

On 29 October 2024 the Pharmacy Compounding Advisory Committee reviewed ipamorelin for growth hormone deficiency and postoperative ileus and voted against adding it to the 503A bulks list; the FDA had recommended against it before the meeting.

Ipamorelin acetate nonetheless remains on the 503B Category 2 list for outsourcing facilities, where the flag is specific rather than generic: immunogenicity risk arising from aggregation and from peptide-related impurities. That is a statement about what can go wrong in the manufacture of this class of molecule, and it applies with more force, not less, to a vial produced outside any regulated facility.